Galmed Pharmaceuticals (GLMD) Projected to Announce Quarterly Earnings on Thursday

Galmed Pharmaceuticals (NASDAQ:GLMD) is expected to issue its results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.39) per share for the quarter.

Galmed Pharmaceuticals Stock Down 2.7%

Galmed Pharmaceuticals stock opened at $0.50 on Thursday. The stock has a 50-day moving average price of $0.59 and a 200 day moving average price of $0.64. The company has a market capitalization of $2.77 million, a price-to-earnings ratio of -0.55 and a beta of 0.75. Galmed Pharmaceuticals has a 52 week low of $0.41 and a 52 week high of $2.09.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Galmed Pharmaceuticals currently has an average rating of “Sell”.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.